Clinical aspects and treatments of asthma bronchiale

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorBimra, Jaspreet Kaur
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2017-12-29T10:43:21Z
dc.date.available2017-12-29T10:43:21Z
dc.date.created2017-06-02
dc.description.abstractAsthma bronchiale is a common chronic inflammatory disease of the airways, causing increased secrection of mucus and narrowing airways. This results in frequent episodes of wheezing, breathlessness, coughing and chest tightness. Eosinophils, Neutrophils and Mast cells are some of the mediators involved in the inflammation. Several factors trigger asthma including genetic predisposition, environmental and immunologic factors. Atopic (extrinsic) asthma is caused by IgE - mediated reaction by binding to Mast cells and releasing mediators like histamine, chemokines and cytokines. Non-Atopic (intrinsic) asthma is elicit by non-immune stimuli like stress, exercise, aspirin, viruses, cold and inhaled irritants. Asthma can be classified according to severity (mild, moderate, severe) of the disease. Treatment is given according to the severity, and is divided into reliever and controller medication. Reliever medication is given for relieving symptoms like bronchoconstriction within few minutes. Salbutamol (SABA) and Ipratropium bromide (anticholinergic drug) are reliever drugs either used separately or together. ICS used together with LABA gives a long acting effect and are used as controller medication. LTRA, Theophylline and Cromolyn Sodium are also used. Omalizumab is used in anti-IgE therapy and is beneficial for severe allergic asthma. It is used as a long acting agent and shows a decrement in the recurrence and severity of asthma exacerbations. It has also reduced the amount of patients visiting the emergency departments by improving both FEV1 and morning PEF. Future treatments for asthma include several different humanized monoclonal antibodies which targets different sites in the inflammatory cascade. Also the use of herbal therapy has proven to be beneficial for asthma, but still needs more recognition and research. Patients should be provided with education and training from health care professionals, or from other helpful sources to use inhalers properly for most beneficial outcome.hu_HU
dc.description.correctorhbk
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.coursespecOrvosbiológia-farmakológiahu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent38hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/246728
dc.language.isoenhu_HU
dc.subjectasthma bronchialehu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleClinical aspects and treatments of asthma bronchialehu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)